Moleculin enrolls 45th subject in MIRACLE AML trial; interim data unblinding on track for mid-2026

Moleculin Biotech, Inc.

45th subject enrolled in pivotal Phase 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML.
Interim unblinding of first 45 subjects remains on track for mid-2026; CEO calls it potentially the most important data moment.
Early blinded data among first 30 patients showed 40% composite complete remission rate (30% CR, 10% CR with partial hematologic recovery).
Approximately 35% of subjects had previously failed venetoclax-based therapies; many had adverse genetic markers.
Enrollment progressing toward 90-subject Part A completion expected in Q3 2026; Phase 3 design to follow dose determination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.